Deficiency of a potential 3p21.3 tumor suppressor gene UBE1L (UBA7) does not accelerate lung cancer development in K-rasLA2 mice

Lung Cancer

Volumn 63, Issue 2, 2009, Pages 194-200

  Yin, Xiaoyan ^a   Cong, Xiuli ^a,b   Yan, Ming ^a,b   Zhang, Dong Er ^a,b,c  

^a SCRIPPS RESEARCH INSTITUTE   (United States)

^b UNIVERSITY OF CALIFORNIA SAN DIEGO   (United States)

^c UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

ISG15; ISGylation; K ras; Mouse cancer model; Tumor suppressor gene; UBE1L

Indexed keywords

K RAS PROTEIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CANCER GROWTH; CANCER SURVIVAL; CONJUGATION; CONTROLLED STUDY; DISEASE COURSE; LUNG CANCER; MOUSE; NONHUMAN; PRIORITY JOURNAL; TUMOR SUPPRESSOR GENE; UBE1L GENE;

ANIMALS; CYTOKINES; GENES, RAS; GENES, TUMOR SUPPRESSOR; LUNG NEOPLASMS; LYMPHOMA; MICE; THYMUS GLAND; UBIQUITIN-ACTIVATING ENZYMES; UBIQUITINS;

EID: 58049205735     PISSN: 01695002     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.lungcan.2008.05.009     Document Type: Article

References (42)

1. Jemal A., Chu K.C., and Tarone R.E. Recent trends in lung cancer mortality in the United States. J Natl Cancer Inst 93 4 (2001) 277-283
2. Massior P.P. Genomic alterations in lung cancer. In: Pass H.I., Carbone D.P., Johnson D.H., Minna J.D., and Turrisi III A.T. (Eds). Lung cancer: principles and practice (2005), Lippincott William & Wilkins, Philadelphia 77-96
3. Satoh H., Lamb P.W., Dong J.T., Everitt J., Boreiko C., Oshimura M., et al. Suppression of tumorigenicity of A549 lung adenocarcinoma cells by human chromosomes 3 and 11 introduced via microcell-mediated chromosome transfer. Mol Carcinogen 7 3 (1993) 157-164
4. Todd M.C., Xiang R.H., Garcia D.K., Kerbacher K.E., Moore S.L., Hensel C.H., et al. An 80 Kb P1 clone from chromosome 3p21.3 suppresses tumor growth in vivo. Oncogene 13 11 (1996) 2387-2396
5. Zabarovsky E.R., Lerman M.I., and Minna J.D. Chromosome 3 abnormalities in lung cancer. In: Pass H.I., Carbone D.P., Johnson D.H., Minna J.D., and Turrisi III A.T. (Eds). Lung cancer: principles and practice (2005), Lippincott William & Wilkins, Philadelphia 118-134
6. Hesson L.B., Cooper W.N., and Latif F. Evaluation of the 3p21.3 tumour-suppressor gene cluster. Oncogene 26 52 (2007) 7283-7301
7. Kok K., van den B.A., Buchhagen D.L., Carritt B., and Buys C.H. A PCR-aided transcript titration assay revealing very low expression of a gene at band 3p21 in 33 cells lines derived from all types of lung cancer. Eur J Hum Genet 1 2 (1993) 156-163
8. Kok K., Hofstra R., Pilz A., van den B.A., Terpstra P., Buys C.H., et al. A gene in the chromosomal region 3p21 with greatly reduced expression in lung cancer is similar to the gene for ubiquitin-activating enzyme. Proc Natl Acad Sci USA 90 13 (1993) 6071-6075
9. Carritt B., Kok K., van den B.A., Osinga J., Pilz A., Hofstra R.M., et al. A gene from human chromosome region 3p21 with reduced expression in small cell lung cancer. Cancer Res 52 6 (1992) 1536-1541
10. Pitha-Rowe I., Petty W.J., Feng Q., Koza-Taylor P.H., Dimattia D.A., Pinder L., et al. Microarray analyses uncover UBE1L as a candidate target gene for lung cancer chemoprevention. Cancer Res 64 21 (2004) 8109-8115
11. Dragnev K.H., Feng Q., Ma Y., Shah S.J., Black C., Memoli V., et al. Uncovering novel targets for cancer chemoprevention. Recent Results Cancer Res 174 (2007) 235-243
12. Dao C.T., and Zhang D.E. ISG15: a ubiquitin-like enigma. Front Biosci 10 (2005) 2701-2722
13. Kim K.I., Yan M., Malakhova O., Luo J.K., Shen M.F., Zou W., et al. Ube1L and protein ISGylation are not essential for alpha/beta interferon signaling. Mol Cell Biol 26 2 (2006) 472-479
14. Giannakopoulos N.V., Luo J.K., Papov V., Zou W., Lenschow D.J., Jacobs B.S., et al. Proteomic identification of proteins conjugated to ISG15 in mouse and human cells. Biochem Biophys Res Commun 336 2 (2005) 496-506
15. Malakhov M.P., Kim K.I., Malakhova O.A., Jacobs B.S., Borden E.C., and Zhang D.E. High-throughput immunoblotting. Ubiquitin-like protein ISG15 modifies key regulators of signal transduction. J Biol Chem 278 19 (2003) 16608-16613
16. Wong J.J., Pung Y.F., Sze N.S., and Chin K.C. HERC5 is an IFN-induced HECT-type E3 protein ligase that mediates type I IFN-induced ISGylation of protein targets. Proc Natl Acad Sci USA 103 28 (2006) 10735-10740
17. Zhao C., Denison C., Huibregtse J.M., Gygi S., and Krug R.M. Human ISG15 conjugation targets both IFN-induced and constitutively expressed proteins functioning in diverse cellular pathways. Proc Natl Acad Sci USA 102 29 (2005) 10200-10205
18. Der C.J., Krontiris T.G., and Cooper G.M. Transforming genes of human bladder and lung carcinoma cell lines are homologous to the ras genes of Harvey and Kirsten sarcoma viruses. Proc Natl Acad Sci USA 79 11 (1982) 3637-3640
19. Malumbres M., and Barbacid M. RAS oncogenes: the first 30 years. Nat Rev Cancer 3 6 (2003) 459-465
20. Downward J. Targeting RAS signalling pathways in cancer therapy. Nat Rev Cancer 3 1 (2003) 11-22
21. Platanias L.C. Mechanisms of type-I- and type-II-interferon-mediated signalling. Nat Rev Immunol 5 5 (2005) 375-386
22. Johnson L., Mercer K., Greenbaum D., Bronson R.T., Crowley D., Tuveson D.A., et al. Somatic activation of the K-ras oncogene causes early onset lung cancer in mice. Nature 410 6832 (2001) 1111-1116
23. Farr A., Nelson A., Truex J., and Hosier S. Epithelial heterogeneity in the murine thymus: a cell surface glycoprotein expressed by subcapsular and medullary epithelium. J Histochem Cytochem 39 5 (1991) 645-653
24. Hoeller D., Hecker C.M., and Dikic I. Ubiquitin and ubiquitin-like proteins in cancer pathogenesis. Nat Rev Cancer 6 10 (2006) 776-788
25. Watson I.R., and Irwin M.S. Ubiquitin and ubiquitin-like modifications of the p53 family. Neoplasia 8 8 (2006) 655-666
26. Menin C., Scaini M.C., De Salvo G.L., Biscuola M., Quaggio M., Esposito G., et al. Association between MDM2-SNP309 and age at colorectal cancer diagnosis according to p53 mutation status. J Natl Cancer Inst 98 4 (2006) 285-288
27. Lind H., Zienolddiny S., Ekstrom P.O., Skaug V., and Haugen A. Association of a functional polymorphism in the promoter of the MDM2 gene with risk of nonsmall cell lung cancer. Int J Cancer 119 3 (2006) 718-721
28. Mo Y.Y., Yu Y., Theodosiou E., Rachel Ee P.L., and Beck W.T. A role for Ubc9 in tumorigenesis. Oncogene 24 16 (2005) 2677-2683
29. Kitareewan S., Pitha-Rowe I., Sekula D., Lowrey C.H., Nemeth M.J., Golub T.R., et al. UBE1L is a retinoid target that triggers PML/RARalpha degradation and apoptosis in acute promyelocytic leukemia. Proc Natl Acad Sci USA 99 6 (2002) 3806-3811
30. Pitha-Rowe I., Hassel B.A., and Dmitrovsky E. Involvement of UBE1L in ISG15 conjugation during retinoid-induced differentiation of acute promyelocytic leukemia. J Biol Chem 279 18 (2004) 18178-18187
31. Desai S.D., Haas A.L., Wood L.M., Tsai Y.C., Pestka S., Rubin E.H., et al. Elevated expression of ISG15 in tumor cells interferes with the ubiquitin/26S proteasome pathway. Cancer Res 66 2 (2006) 921-928
32. Andersen J.B., Aaboe M., Borden E.C., Goloubeva O.G., Hassel B.A., and Orntoft T.F. Stage-associated overexpression of the ubiquitin-like protein, ISG15, in bladder cancer. Br J Cancer 94 10 (2006) 1465-1471
33. Farrell P.J., Broeze R.J., and Lengyel P. Accumulation of an mRNA and protein in interferon-treated Ehrlich ascites tumour cells. Nature 279 5713 (1979) 523-525
34. D'Cunha J., Knight Jr. E., Haas A.L., Truitt R.L., and Borden E.C. Immunoregulatory properties of ISG15, an interferon-induced cytokine. Proc Natl Acad Sci USA 93 1 (1996) 211-215
35. D'Cunha J., Ramanujam S., Wagner R.J., Witt P.L., Knight Jr. E., and Borden E.C. In vitro and in vivo secretion of human ISG15, an IFN-induced immunomodulatory cytokine. J Immunol 157 9 (1996) 4100-4108
36. Owhashi M., Taoka Y., Ishii K., Nakazawa S., Uemura H., and Kambara H. Identification of a ubiquitin family protein as a novel neutrophil chemotactic factor. Biochem Biophys Res Commun 309 3 (2003) 533-539
37. Lenschow D.J., Giannakopoulos N.V., Gunn L.J., Johnston C., O'Guin A.K., Schmidt R.E., et al. Identification of interferon-stimulated gene 15 as an antiviral molecule during Sindbis virus infection in vivo. J Virol 79 22 (2005) 13974-13983
38. Lenschow D.J., Lai C., Frias-Staheli N., Giannakopoulos N.V., Lutz A., Wolff T., et al. IFN-stimulated gene 15 functions as a critical antiviral molecule against influenza, herpes, and Sindbis viruses. Proc Natl Acad Sci USA 104 4 (2007) 1371-1376
39. Wistuba I.I., Gazdar A.F., and Minna J.D. Molecular genetics of small cell lung carcinoma. Semin Oncol 28 2 Suppl. (4) (2001) 3-13
40. Mills N.E., Fishman C.L., Rom W.N., Dubin N., and Jacobson D.R. Increased prevalence of K-ras oncogene mutations in lung adenocarcinoma. Cancer Res 55 7 (1995) 1444-1447
41. Wakamatsu N., Devereux T.R., Hong H.H., and Sills R.C. Overview of the molecular carcinogenesis of mouse lung tumor models of human lung cancer. Toxicol Pathol 35 1 (2007) 75-80
42. Nikitin A.Y., Alcaraz A., Anver M.R., Bronson R.T., Cardiff R.D., Dixon D., et al. Classification of proliferative pulmonary lesions of the mouse: recommendations of the mouse models of human cancers consortium. Cancer Res 64 7 (2004) 2307-2316